Achillion Pharmaceut (ACHN) 8.37 $ACHN ACHN March 2017

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Achillion Pharmaceut (ACHN) 8.37 $ACHN

ACHN March 2017 Options Begin Trading
DividendChannel.com - Mon Jul 18, 10:24AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the March 2017 expiration.
ACHN: 8.37 (+0.09)

Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
GlobeNewswire - Fri Jun 10, 2:30AM CDT
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
ACHN: 8.37 (+0.09)

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.37 (+0.09), JAZZ: 150.18 (-0.79), GRFS: 16.90 (-0.04), PBYI: 50.38 (+0.49)

Achillion to Present at Three Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:02PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences:
ACHN: 8.37 (+0.09)

Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:05AM CDT
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers -
ACHN: 8.37 (+0.09)

Achillion reports 1Q loss
Automated Insights - Tue May 03, 5:19AM CDT
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $18.1 million in its first quarter.
ACHN: 8.37 (+0.09)

Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
GlobeNewswire - Tue May 03, 5:05AM CDT
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 -
ACHN: 8.37 (+0.09)

Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Thu Apr 28, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 Annual Health Care Conference on Thursday, May 5, 2016 at 1:30 p.m. EDT at The InterContinental Hotel in Boston, MA.
ACHN: 8.37 (+0.09), DB: 13.16 (-0.28)

Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:02AM CDT
Investors certainly have to be happy with Achillion Pharmaceuticals, Inc. (ACHN) and its short term performance
ACHN: 8.37 (+0.09)

First Week of December 16th Options Trading For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Tue Apr 19, 9:57AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the December 16th expiration.
ACHN: 8.37 (+0.09)

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
GlobeNewswire - Thu Mar 24, 7:09AM CDT
ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank Verwiel, MD to its Board of Directors. Over the last 25 years, Dr. Verwiel has amassed a wealth of knowledge across multiple operational, development, and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Most recently, Dr. Verwiel was President and Chief Executive Officer of Aptalis Pharma, Inc. (formerly Axcan Pharma Inc.), which was acquired by Forest Laboratories for $2.9 billion in 2014.
ACHN: 8.37 (+0.09), AVXS: 35.99 (-1.64)

Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 125.12 (-0.11), INO: 10.26 (+0.38), ACHN: 8.37 (+0.09), GSK: 44.99 (-0.08), NVS: 82.98 (-0.28), CELGZ: 1.12 (-0.04)

Why Achillion Pharmaceuticals Shares Crashed 37% in January
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 04, 2:40PM CST
Image source: Achillion Pharmaceuticals. W hat: Despite announcing a key new hire last month, shares in the clinical-stage drugmaker Achillion Pharmaceuticals dropped 37.3% in January, according to S&P Capital IQ. So what: On Jan....
JNJ: 125.12 (-0.11), GILD: 79.70 (+0.23), ACHN: 8.37 (+0.09), BMY: 75.41 (+0.60)

Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
GlobeNewswire - Wed Feb 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, Ph.D., recently joined the Company and will serve as Senior Vice President of Regulatory Affairs.
ACHN: 8.37 (+0.09)

Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 8:30AM CST
Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
LC: 4.59 (-0.03), OPK: 9.94 (-0.01), ACHN: 8.37 (+0.09), CUDA: 22.25 (+0.17), ENT: 8.40 (+0.20)

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Review - H2 2015 Report
M2 - Wed Jan 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnv8gp/paroxysmal) has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Paroxysmal Nocturnal Hemoglobinuria Overview - Therapeutics Development - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Comparative Analysis - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Products under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development - Achillion Pharmaceuticals, Inc. - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Apellis Pharmaceuticals, Inc. - Epirus Biopharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Ra Pharmaceuticals, Inc. - Regenesance BV - The International Biotechnology Center (IBC) Generium For more information visit http://www.researchandmarkets.com/research/nnv8gp/paroxysmal
ACHN: 8.37 (+0.09), ALXN: 132.11 (+3.51), OMER: 11.92 (+0.16), NVS: 82.98 (-0.28)

A Company's First Profit Can Mean Big Profits to Investors
Kevin Matras - Zacks Investment Research - Tue Jan 26, 2:04PM CST
A Company's First Profit Can Mean Big Profits to Investors
LC: 4.59 (-0.03), OPK: 9.94 (-0.01), ACHN: 8.37 (+0.09), CUDA: 22.25 (+0.17), ENT: 8.40 (+0.20)

The Zacks Analyst Blog Highlights: Gilead, Horizon Pharma, AVEO Pharmaceuticals, Achillion Pharmaceuticals and Inovio Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead, Horizon Pharma, AVEO Pharmaceuticals, Achillion Pharmaceuticals and Inovio Pharmaceuticals
INO: 10.26 (+0.38), GILD: 79.70 (+0.23), ACHN: 8.37 (+0.09), AVEO: 1.01 (+0.01), HZNP: 19.62 (+0.33)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 150

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 176

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 161

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 191

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 261

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Alliance Between Vireo and Curio Enhances Growth Opportunities

Updated Category News Views 201

Strategic Partnership Announced Leading cannabis companies Vireo Growth Inc. and Curio Wellness have forged a partnership aimed at leveraging shared resources to tap into the burgeoning cannabis market. This collaboration marks an exciting new chapter for both companies as they work to introduce innovative health and wellness products to consumers. Vireo Growth Inc.: A...

Continue Reading
G42 and Mistral AI Collaborate for Innovative AI Solutions

Updated Category News Views 251

Strategic Partnership between G42 and Mistral AI In a significant development for global artificial intelligence, G42, a technology group based in Abu Dhabi, has teamed up with Mistral AI, a reputable AI company headquartered in Paris. This partnership was announced during the Choose France event and stands as a testament to the collaborative spirit between the UAE and...

Continue Reading
Trellus Marketplace Launches: A New Era for Local Shopping

Updated Category News Views 303

Launch of Trellus Marketplace Revolutionizes Local Shopping Trellus Marketplace has made a significant entrance into the e-commerce world, becoming the first platform entirely dedicated to the unique offerings of Long Island's small businesses. This innovative online marketplace allows consumers to shop for local goods directly from their desktops, iOS, and Android...

Continue Reading
Gunderson Dettmer Expands Leadership with New Chief Revenue Officer

Updated Category News Views 275

Gunderson Dettmer Welcomes Erin Stone Dimry Gunderson Dettmer is thrilled to announce the appointment of Erin Stone Dimry as the Chief Revenue Officer. As a global leader in the innovation economy, the firm recognizes the importance of strategic leadership for its continued growth and success. Significance of Erin's Role In her new position, Erin will collaborate closely...

Continue Reading
Newly Approved Services by AB Ignitis Gamyba Benefit Consumers

Updated Category News Views 203

Introduction to the New Regulations AB “Ignitis grup?” has announced a significant development regarding the services provided by its subsidiary, AB “Ignitis gamyba.” The National Energy Regulatory Council (NERC) has recently approved a resolution aimed at amending previous regulations pertaining to the methodology for calculating electricity prices and other...

Continue Reading